Memantină Grindeks

Memantine Hydrochloride, the active ingredient in Memantína Grindeks, is an NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memantína Grindeks as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantína Grindeks is an NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders. - Moderate to severe Alzheimer’s disease: helps maintain cognitive function and daily activities. - Alzheimer’s disease with behavioral disturbances: may reduce agitation and aggression. - Patients intolerant to cholinesterase inhibitors: provides an alternative mechanism of action.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with dietary fiber. - Fatigue: feeling of tiredness that may improve over time.

Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hepatic dysfunction: elevated liver enzymes indicating possible liver injury.

Memantína Grindeks should be used with caution in specific clinical situations. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic disease: monitor liver enzymes regularly. - Cardiovascular disorders: watch for changes in blood pressure or heart rate. - Concomitant CNS‑active drugs: may increase dizziness or confusion. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Memantína Grindeks may interact with several medicines; awareness helps prevent adverse outcomes. Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - Ketamine: additive effects on NMDA blockade may exacerbate CNS depression. - High‑dose quinidine: may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): can enhance dizziness and sedation. - Diuretics: may affect blood pressure, requiring closer monitoring.